MAPT and Alzheimer disease: Higher MK6240 binding was observed in early‐onset compared with late‐onset AD as measured in post‐mortem brain tissues (Malarte et al. 2021), and the MK6240 tracer showed enhanced sensitivity over previously developed tau tracers (Gogola et al. 2022).